Written question asked by Amy Callaghan (Scottish National Party) on Monday, 16 May 2022, in the House of Commons. It was due for an answer on Wednesday, 18 May 2022. It was answered by Maggie Throup (Conservative) on Tuesday, 24 May 2022 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question: To ask the Secretary of State for Health and Social Care, whether the Government plans to procure the Evusheld drug for treatment of covid-19 for clinically extremely vulnerable people.

Original answer: On 17 March 2022, Evusheld was granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency (MHRA). However, the MHRA highlighted uncertainty over the appropriate dose needed for protection against the Omicron variant. Understanding its efficacy is necessary prior to any procurement or deployment decisions. The UK Health Security Agency is currently undertaking further testing on the treatment’s effectiveness against the Omicron variant to inform any such decisions.

It has since been corrected.

Secondary information

Type: Written question
Reference: 2654
Session: 2022-23
Related items: Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Commons; Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Lords
Notes: Information corrected on 17 April at 731 c10-2WS
Subjects: Immunosuppression Tixagevimab/cilgavimab
Link: View this Written question on www.parliament.uk